ArticleDiscover oncology2025
Construction and validation of a cell-in-cell related prognostic signature for hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cell-in-cell structures (CICs) and their biological roles contribute to disease development, particularly in cancer. However, the roles of CIC-associated genes (CICGs) in hepatocellular carcinoma (HCC) are largely unknown. This study sought to establish a a CICGs-linked HCC signature and assess its predictive significance. We acquired gene expression profiling data for tumor and normal tissues of HCC patients from The Cancer Genome Atlas (TCGA) for training and from the International Cancer Genome Consortium (ICGC) for validation. Consensus clustering was employed to delineate patient cohorts with varying prognoses, categorizing HCC patients into two distinct groups. A selection of fifty CICGs was compiled from the literature, revealing their association with CIC development through functional studies. Six predictive genes were ultimately identified through univariate Cox proportional hazards regression (Cox) and least absolute shrinkage and selection operator (LASSO) analyses. This prognostic signature, resulting from a multivariate Cox, subsequently segmented TCGA and ICGC cohort individuals into high- and low-risk categories. Our verification of the signature's precision involved survival analysis contrasts between those at high and low risk. Quantitative real-time PCR (qRT-PCR) analysis revealed markedly elevated expression levels of these six genes in HCC tumors compared to neighboring healthy tissue, underscoring their potential role in tumor development. This experimentally reinforces the accuracy of the genetic profile. We also examined variations in the composition of immune cells and immunological responses across high-risk and low-risk cohorts. This study established and verified prognostic variables connected to cell-in-cell (CIC), potentially improving personalized survival forecasts for patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.